On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved epcoritamab-bysp (Epkinly, co-developed by Genmab and AbbVie) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. “The…
Lymphoma Research Foundation Awards More Than $5.4 Million in Lymphoma Research Grants New York, NY (May 1, 2023) – The Lymphoma Research Foundation (LRF), the nation’s largest nonprofit organization devoted to funding innovative lymphoma research and serving the lymphoma community,…
On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL),…
On April 6, 2023, AbbVie announced its intent to withdraw the accelerated approval of ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who…
The Importance of Being Seen and Heard In April 2021, Paula Ngon was an active, young public relations professional living in New York City, navigating life amid a global pandemic. One day, not feeling well and concerned about swollen lymph…
Updates from the 2022 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 300 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax Investigators reported updated results from a phase II trial exploring the use of ibrutinib-venetoclax combination therapy in patients with high-risk…
ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy Consolidation with either whole-brain radiation therapy (WBRT) or autologous stem cell transplant (autoSCT) improves overall survival in patients with primary central nervous system lymphoma (PCNSL), regardless of first-line…
ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Combination therapy with rituximab (Rituxan) and lenalidomide (Revlimid) was approved for use in relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) based on the results…